Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 4, Efficacy and Safety of Atusin CAP in the Treatment of Subjects With Acute Bronchitis in the Primary Healthcare Setting: Prospective, Multicenter, Double-blind, Placebo-controlled, Randomized, Parallel-arm Clinical Study.

NCT06142994 is registered in ClinicalTrials.gov with Neopharm Bulgaria Ltd. as lead sponsor.

NCT NCT06142994
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06142994 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 4, Efficacy and Safety of Atusin CAP in the Treatment of Subjects With Acute Bronchitis in the Primary Healthcare Setting: Prospective, Multicenter, Double-blind, Placebo-controlled, Randomized, Parallel-arm Clinical Study.
Lead sponsor
Neopharm Bulgaria Ltd.
Phase
Not applicable
Overall status
Completed
Start date
January 30, 2024
Completion date
June 20, 2024
Enrollment
310 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute bronchitis